Advanced Therapeutics最新文献_第3页

Self-Assembled Nanocarriers of Synthetic and Natural Plasmalogens for Potential Nanomedicine Development (Adv. Therap. 2/2025) 用于潜在纳米药物开发的合成和天然缩醛原自组装纳米载体（Adv. therapy . 2/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-02-13 DOI: 10.1002/adtp.202570004

Yu Wu, Borislav Angelov, Yuru Deng, Takehiko Fujino, Md Shamim Hossain, Thomas Bizien, Angelina Angelova

引用次数: 0

Issue Information (Adv. Therap. 2/2025) 发行信息（ad . therapy . 2/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-02-13 DOI: 10.1002/adtp.202570005

引用次数: 0

Photothermal Therapy: From Encouraging Lab Results to Lackluster Clinical Translation 光热疗法：从令人鼓舞的实验室结果到平淡的临床转化

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-02-09 DOI: 10.1002/adtp.202400347

Jonathan Buiel, Jordan Robert, Dikran Mekhjian, Deepak S. Chauhan, Xavier Banquy

{"title":"Photothermal Therapy: From Encouraging Lab Results to Lackluster Clinical Translation","authors":"Jonathan Buiel, Jordan Robert, Dikran Mekhjian, Deepak S. Chauhan, Xavier Banquy","doi":"10.1002/adtp.202400347","DOIUrl":"https://doi.org/10.1002/adtp.202400347","url":null,"abstract":"Cancer is a pervasive and complex disease that poses a significant threat to public health worldwide. The prevalent therapeutic options, including chemotherapy and radiotherapy, pose detrimental side effects. Consequently, non-invasive and selective therapeutic strategies are sought, such as nanoparticle-mediated photothermal therapy (PTT). This technique employs benign photothermal agents that gather within tumors post-injection. Under near-infra-red light exposure, these agents induce localized hyperthermia, killing tumor cells. Here, the laboratory development, recent advances, and clinical status of photothermal therapy are examined. Despite two decades of development, photothermal therapy has yielded few clinical trials. A standout agent, the gold nanoshell, holds promise for prostate cancer treatment as the only one in human clinical trials. To provide context, PTT is compared to photodynamic therapy, which has over 250 human trials in 40 years, highlighting the need to bridge the gap for effective photothermal therapy translation. Therefore, we delve into the gap of clinical implementation between photothermal therapy and similar technologies, such as photodynamic therapy, laser interstitial thermal therapy, and cancer nanomedicines, offering insights and potential solutions.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400347","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143645953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Engineering Eutectogel Microneedle Patch as Effective Transdermal Delivery System of Hydrophobic Drugs

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-02-09 DOI: 10.1002/adtp.202400521

Danilo M. dos Santos, Hasika Suresh, Samantha J. Kruzshak, Jihyun Kim, Peggy Cebe, James D. Baleja, Emmanuel S. Tzanakakis, Sameer Sonkusale

{"title":"Engineering Eutectogel Microneedle Patch as Effective Transdermal Delivery System of Hydrophobic Drugs","authors":"Danilo M. dos Santos, Hasika Suresh, Samantha J. Kruzshak, Jihyun Kim, Peggy Cebe, James D. Baleja, Emmanuel S. Tzanakakis, Sameer Sonkusale","doi":"10.1002/adtp.202400521","DOIUrl":"https://doi.org/10.1002/adtp.202400521","url":null,"abstract":"Conventional drug delivery methods often face challenges in terms of patient adherence and drug administration. Microneedles (MNs) patches have emerged as a promising alternative, offering a minimally invasive transdermal route for medications. However, their drug-loading capacity remains limited, particularly for hydrophobic active pharmaceutical ingredients (APIs). Herein, microneedles are designed based on eutectic solvent gels (eutectogels) as transdermal carriers for hydrophobic APIs. A natural deep eutectic solvent (NADES) is combined to enhance the solubility of the hydrophobic APIs within the GelMA/PEGDA matrix for mechanical strength and sustained release from the resulting eutectogels microneedles (EU-MNs). Using docetaxel, 5-fluorouracil, and curcumin as hydrophobic APIs models, the superior drug-loading capacity of the EU-MNs is demonstrated. In vitro experiments revealed that the EU-MNs provided a sustained release of distinct hydrophobic APIs over 4 days. Additionally, by properly adjusting the concentration and type of APIs, these microneedle patches do not exhibit cytotoxic effects on fibroblasts cell line (NIH/3T3), underscoring their potential for safe and effective transdermal drug delivery. These findings highlight the potential of EU-MNs as versatile, eco-friendly transdermal vehicles for large amounts of hydrophobic APIs, leading to more effective treatments for these drugs.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Copper Ions in Mediating the Anti-Cancer Effects Using Nanomaterials 铜离子在纳米材料抗癌中的作用

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-02-03 DOI: 10.1002/adtp.202400426

Irfan Mehmud, Song Wu, Shaohua Zhang

{"title":"The Role of Copper Ions in Mediating the Anti-Cancer Effects Using Nanomaterials","authors":"Irfan Mehmud, Song Wu, Shaohua Zhang","doi":"10.1002/adtp.202400426","DOIUrl":"https://doi.org/10.1002/adtp.202400426","url":null,"abstract":"Copper plays a pivotal role in human physiology, particularly in oncology, acting both as a facilitator of progression and also as a potential avenue for advanced therapeutic approaches. Maintaining copper homeostasis is crucial. The dysregulation of copper homeostasis is implicated in tumor growth through its involvement in critical processes of angiogenesis, proliferation, and metastasis. The elevation in copper level in the tumor microenvironment (TME) activates oncogenic pathways to drive the neovascularization and sustained growth of malignancies. However, the same reliance on copper offers a unique weakness that can be leveraged for innovative therapeutic interventions. The recent advances in nanomedicine enable the synthesis of nanostructures that can help modulate the level of copper with precision offering multifaceted approaches for copper-based cancer therapy with controlled release mechanism, optimized structures to induce cuproptosis, selective eradication of cancer cells with minimum and systemic toxicity. This review explores the dual role of copper in cancer biology, emphasizing its contribution to the progression of tumors and its emerging application in targeted cancer therapy. The review also highlights the potential of nanostructures in harnessing copper-based therapies and their transformative potential from bench to bed side with novel, highly effective, and clinical safety.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eltrombopag Inhibited Liver Cancer by Enhancing SMYD4 Protein Degradationvia TRIP12 Ubiquitinase Eltrombopag通过TRIP12泛素酶促进SMYD4蛋白降解抑制肝癌

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-02-03 DOI: 10.1002/adtp.202400372

Jiale Li, Qiqiang Zhang, Chunyan Wang, Shupeng Liu

{"title":"Eltrombopag Inhibited Liver Cancer by Enhancing SMYD4 Protein Degradationvia TRIP12 Ubiquitinase","authors":"Jiale Li, Qiqiang Zhang, Chunyan Wang, Shupeng Liu","doi":"10.1002/adtp.202400372","DOIUrl":"https://doi.org/10.1002/adtp.202400372","url":null,"abstract":"According to prior studies, SET and MYND domain-containing protein 4 (SMYD4) is involved in tumor progression and metastasis, representing a potential therapeutic target for tumors. However, no specific inhibitors or drugs targeting SMYD4 are currently available. In this study, molecular docking and molecular dynamics simulations were used to screen small molecule lead compounds binding to SMYD4 protein. CCK8 assay, colony formation assay, EdU assay were used to analyze the viability and proliferation of tumor cells. Flow cytometric analysis was used to evaluate cell apoptosis and cell cycle. Clorazepate, Ativan, Darifenacin and Eltrombopag were found to bind with SMYD4 with the highest probability and to meet the five principles of the drug class. Molecular dynamics simulations showed that Eltrombopag had the strongest binding capacity to SMYD4 protein. The functional analysis showed that Eltrombopag inhibited hepatocellular carcinoma cell proliferation and promoted apoptosis in vivo and in vitro at low density. Moreover, Eltrombopag enhanced ubiquitination of SMYD4 protein and promoted its degradation via thyroid hormone receptor interactor 12(TRIP12). These findings suggest that Eltrombopag is a potential inhibitor of SMYD4 protein, representing a novel leading compound for SMYD4 and applied for tumor treatment.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 2","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143396757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dermal Substitutes for Clinical Management of Severe Burn Injuries: Current and Future Perspectives 严重烧伤临床治疗的皮肤替代品：当前和未来的观点

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-01-23 DOI: 10.1002/adtp.202400455

Van Vo, Hanif Haidari, Allison J. Cowin, Marcus Wagstaff, Bronwyn Dearman, Zlatko Kopecki

{"title":"Dermal Substitutes for Clinical Management of Severe Burn Injuries: Current and Future Perspectives","authors":"Van Vo, Hanif Haidari, Allison J. Cowin, Marcus Wagstaff, Bronwyn Dearman, Zlatko Kopecki","doi":"10.1002/adtp.202400455","DOIUrl":"https://doi.org/10.1002/adtp.202400455","url":null,"abstract":"Despite significant advances in recent decades, severe burns remain a formidable challenge, with high morbidity and mortality rates. The immunocompromised state following severe burn injuries, compounded by the loss of the protective skin barrier, increases the risk of bacterial colonization and invasion. Without appropriate management, infections in burn patients can progress to sepsis, a life-threatening complication. Current burn care often fails to achieve optimal tissue regeneration and infection prevention, necessitating a combination of different approaches. Developing innovative and safer strategies to mitigate burn infections is essential for improving patient outcomes. This review provides updated insights into various biomaterials tailored for managing infections in severe burns, offering comprehensive insights and a summary of emerging technologies for potential clinical application. Additionally, an in-depth discussion on current research and clinical areas that warrant further investigation is presented. Potential avenues for next-generation dermal substitutes aimed at improving regeneration and preventing burn wound infections are then explored.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400455","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bee Better: The Role of Honey in Modern Wound Care 蜜蜂更好：蜂蜜在现代伤口护理中的作用

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-01-23 DOI: 10.1002/adtp.202400502

Léo-Paul Tricou, Natalie Guirguis, Sarah Djebbar, Benjamin R. Freedman, Simon Matoori

引用次数: 0

Targeting VEGF-A in an Immunocompetent Orthotopic Mouse Model of Mesenchymal Glioblastoma Improves Antitumorigenicity and Decreases Proinflammatory Response in Normal Brain Tissue after Fractionated Radiotherapy 靶向VEGF-A的免疫功能小鼠间充质胶质母细胞瘤模型可提高正常脑组织分步放疗后的抗肿瘤性并降低促炎反应

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-01-23 DOI: 10.1002/adtp.202400374

Alexander Edward Nieto, Daniel Felix Fleischmann, Kristian Unger, Valerie Albrecht, Jessica Maas, Horst Zitzelsberger, Claus Belka, Martin Proescholdt, Kirsten Lauber, Maximilian Niyazi, Michael Orth

{"title":"Targeting VEGF-A in an Immunocompetent Orthotopic Mouse Model of Mesenchymal Glioblastoma Improves Antitumorigenicity and Decreases Proinflammatory Response in Normal Brain Tissue after Fractionated Radiotherapy","authors":"Alexander Edward Nieto, Daniel Felix Fleischmann, Kristian Unger, Valerie Albrecht, Jessica Maas, Horst Zitzelsberger, Claus Belka, Martin Proescholdt, Kirsten Lauber, Maximilian Niyazi, Michael Orth","doi":"10.1002/adtp.202400374","DOIUrl":"https://doi.org/10.1002/adtp.202400374","url":null,"abstract":"Glioblastoma is the most aggressive primary brain tumor characterized by a dismal prognosis and a profound therapy resistance that is most evident for the mesenchymal molecular subtype of glioblastoma. Targeting vascular endothelial growth factor (VEGF)-A by the monoclonal antibody bevacizumab, despite failing to improve survival in randomized trials, yields relevant benefits in glioblastoma patients such as reduction of radionecrosis, an adverse event associated with radiotherapy. This demands for continued research to identify optimal combinations of anti-VEGF-A and standard therapies for glioblastoma treatment. We show here that blocking VEGF-A in an immune competent orthotopic glioblastoma mouse model resembling the adverse mesenchymal molecular subtype increases the tumoricidal effect of computed tomography (CT)-based fractionated radiotherapy and also rectifies irradiation-induced expression of genes with known association to mesenchymal subtype enrichment as revealed by microarray-based transcriptome analyses of explanted tumors. VEGF-A blockade also decreases the expression of myeloid-cell-related gene patterns in irradiated tumors and lowers inflammatory response in normal brain tissue after tumor irradiation. Hence, these data both provide a hint how blockade of VEGF-A increases the effect of radiotherapy in mesenchymal glioblastoma and a mechanistic base for clinical observations reporting reduced incidences of radionecrosis in glioblastoma patients treated with radiotherapy upon concurrent administration of bevacizumab.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 2","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400374","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143397349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipopeptide 01 from Staphylococcus Epidermidis Resists Pathogenic Bacteria and Promotes Bone Healing in Implant-Associated Infections 表皮葡萄球菌脂肽01抵抗病原菌并促进种植体相关感染的骨愈合

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-01-19 DOI: 10.1002/adtp.202400477

Shengjie Wang, Wei Liu, Chao Yang, Changwei Li, Xianlong Zhang

{"title":"Lipopeptide 01 from Staphylococcus Epidermidis Resists Pathogenic Bacteria and Promotes Bone Healing in Implant-Associated Infections","authors":"Shengjie Wang, Wei Liu, Chao Yang, Changwei Li, Xianlong Zhang","doi":"10.1002/adtp.202400477","DOIUrl":"https://doi.org/10.1002/adtp.202400477","url":null,"abstract":"Implant-associated infections (IAI) present a significant clinical challenge. Effective prevention of and recovery from IAI is complex, involving antibacterial treatment and the promotion of bone integration. However, the current artificial implants used in clinics often lack effective antibacterial properties and have limited functionality. In this study, Lipopeptide 01 (LP01), a lipopeptide derived from the skin commensal Staphylococcus epidermidis is successfully immobilized, onto the porous surface of sulfonated Poly (ether-ether-ketone) (SPEEK) to create a novel artificial implant, LP01-PS. Both in vivo and in vitro experiments demonstrates that LP01-PS displays favorable material properties, biocompatibility, outstanding antibacterial characteristics, and the ability to promote bone formation. Mechanistically, LP01-PS enhances antibacterial activities by triggering TLR2/P65 signaling, upregulating the expression of LL37 and β-defensins in macrophages. Furthermore, it can boost the osteogenic differentiation capability of bone marrow mesenchymal stem cells (BMSCs) through the β-catenin signaling pathway, thereby facilitating bone formation. The discovery of LP01-PS with dual antibacterial and osteogenic effects, coupled with insights into its mode of action, suggests that LP01-PS can serve as a promising implant material to enhance the success rates of total joint replacement surgeries, mitigate the risks of infection and prosthetic loosening, and foster the repair and regeneration of bone tissue.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143945046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0